A detailed history of Tybourne Capital Management (Hk) LTD transactions in Taysha Gene Therapies, Inc. stock. As of the latest transaction made, Tybourne Capital Management (Hk) LTD holds 3,700,000 shares of TSHA stock, worth $12.7 Million. This represents 2.38% of its overall portfolio holdings.

Number of Shares
3,700,000
Previous 3,700,000 -0.0%
Holding current value
$12.7 Million
Previous $6.55 Million 62.15%
% of portfolio
2.38%
Previous 1.22%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$1.33 - $2.88 $2.93 Million - $6.34 Million
2,200,000 Added 146.67%
3,700,000 $6.55 Million
Q4 2022

Feb 14, 2023

BUY
$1.89 - $2.44 $1.89 Million - $2.44 Million
1,000,000 Added 200.0%
1,500,000 $3.39 Million
Q3 2020

Nov 09, 2020

BUY
$22.4 - $24.47 $11.2 Million - $12.2 Million
500,000 New
500,000 $11.2 Million

Others Institutions Holding TSHA

About Taysha Gene Therapies, Inc.


  • Ticker TSHA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,359,500
  • Market Cap $166M
  • Description
  • Taysha Gene Therapies, Inc., a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for th...
More about TSHA
Track This Portfolio

Track Tybourne Capital Management (Hk) LTD Portfolio

Follow Tybourne Capital Management (Hk) LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tybourne Capital Management (Hk) LTD, based on Form 13F filings with the SEC.

News

Stay updated on Tybourne Capital Management (Hk) LTD with notifications on news.